Specific Populations No clinically significant differences in semaglutide pharmacokinetics were observed based on age (18 years old), sex, race (White, Asian or Black or African American), ethnicity, body weight (40 to 188 kg), upper GI disease (i.e., chronic gastritis and/or gastroesophageal reflux disease), hepatic impairment (i.e., mild, moderate, severe based on the Child-Pugh system) and renal impairment (i.e., mild, moderate, severe, end staged renal disease)
This is why local GCC warehousing is highly favored over international shipping
For quality and high bioavailability, BioBalance is often recommended
What Next
Pricing and red flags
10.1002/advs.202204365 80 YinS.-Y.SongG.YangY.ZhaoY.WangP.ZhuL.-M.et al (2019)